Fusion Pharmaceuticals’ (FUSN) “Hold” Rating Reaffirmed at TD Cowen

Fusion Pharmaceuticals (NASDAQ:FUSN)‘s stock had its “hold” rating restated by stock analysts at TD Cowen in a report issued on Tuesday, Benzinga reports.

FUSN has been the topic of several other reports. SVB Leerink reiterated a “market perform” rating and issued a $21.00 target price (up from $17.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Leerink Partnrs downgraded Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 19th. Brookline Capital Management cut Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. Oppenheimer lifted their price target on Fusion Pharmaceuticals from $13.00 to $15.00 and gave the company an “outperform” rating in a research note on Friday, January 5th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $21.00 price target (up from $10.00) on shares of Fusion Pharmaceuticals in a research note on Tuesday, March 19th. Thirteen equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $20.25.

Fusion Pharmaceuticals Trading Down 0.1 %

Shares of FUSN stock opened at $21.24 on Tuesday. The business’s 50 day moving average is $15.67 and its two-hundred day moving average is $9.63. Fusion Pharmaceuticals has a twelve month low of $2.31 and a twelve month high of $21.55. The company has a market capitalization of $1.80 billion, a P/E ratio of -14.45 and a beta of -0.72. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.16.

Fusion Pharmaceuticals (NASDAQ:FUSN) last announced its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. Equities analysts forecast that Fusion Pharmaceuticals will post -1.46 EPS for the current year.

Institutional Trading of Fusion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of FUSN. Perceptive Advisors LLC purchased a new stake in shares of Fusion Pharmaceuticals in the first quarter valued at $10,405,000. FMR LLC lifted its position in shares of Fusion Pharmaceuticals by 73.9% in the first quarter. FMR LLC now owns 4,681,457 shares of the company’s stock valued at $17,649,000 after acquiring an additional 1,989,403 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of Fusion Pharmaceuticals by 94.1% in the first quarter. Federated Hermes Inc. now owns 3,055,037 shares of the company’s stock valued at $23,738,000 after acquiring an additional 1,481,037 shares in the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Fusion Pharmaceuticals in the first quarter valued at $4,839,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Fusion Pharmaceuticals in the fourth quarter valued at $7,154,000. 72.85% of the stock is currently owned by hedge funds and other institutional investors.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.